Nanoscope Therapeutics is advancing gene therapy using ambient light-sensitive molecules, bringing hope for renewed sight to millions of people blinded by retinal degenerative diseases for which no cure exists.
Latest News from Nanoscope
Press Release: October 10, 2024
Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa
READ COMPLETE PRESS RELEASE
Press Release: September 12, 2024
Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration
Jeff, a patient in our STARLIGHT Clinical Trial for Stargardt Macular Degeneration began to experience vision loss as a young boy. Today, Jeff is seeing more of the world and feeling positive about the future.
Roy, a patient in our RESTORE Clinical Trial for Retinitis Pigmentosa began to experience vision loss 20 years ago. After MCO-010 treatment Roy saw colors he had not seen in years and is now determined to participate in all aspects of his community.
Richard, a patient in our RESTORE Clinical Trial for Retinitis Pigmentosa, talks about the changes MCO-010 treatment has made in his life.
Hear how John, a patient in our RESTORE Clinical Trial for Retinitis Pigmentosa feels about his experience two years after being enrolled in the study.
Hear what a Stargardt Macular Degeneration patient in our STARLIGHT Clinical Trial has to say about her experience.
Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD.
Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
LEARN ABOUT OUR TECHNOLOGY
Our lead gene therapy product in clinical trials for retinitis pigmentosa will be the first therapy to correct the condition and is applicable for patients with complete or partial degeneration of the retina.
Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration
Nanoscope News & Events
-
Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis PigmentosaOctober 10, 2024
-
Nanoscope Therapeutics Licenses Optogenetic CatCh TechnologySeptember 30, 2024
-
Nanoscope Therapeutics to be Featured at Annual EUretina Congress in BarcelonaSeptember 19, 2024
-
Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in BarcelonaSeptember 16, 2024
-
Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular DegenerationSeptember 12, 2024
-
Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in LisbonSeptember 9, 2024
-
Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceAugust 8, 2024
-
Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific MeetingJuly 10, 2024